Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2

被引：4

作者：

Yang, Michael G. ^{[1
]}

Xiao, Zili ^{[1
]}

Zhao, Rulin ^{[1
]}

Tebben, Andrew J. ^{[1
]}

Wang, Bei ^{[1
]}

Cherney, Robert J. ^{[1
]}

Batt, Douglas G. ^{[1
]}

Brown, Gregory D. ^{[1
]}

Cvijic, Mary Ellen ^{[1
]}

Duncia, John, V ^{[1
]}

Gallela, Michael A. ^{[1
]}

Gardner, Daniel S. ^{[1
]}

Khandelwal, Purnima ^{[1
]}

Malley, Mary F. ^{[1
]}

Pang, Jian ^{[1
]}

Rose, Anne, V ^{[1
]}

Santella, Joseph B., III ^{[1
]}

Sarjeant, Amy A. ^{[1
]}

Xu, Songmei ^{[1
]}

Mathur, Arvind ^{[1
]}

Mandlekar, Sandhya ^{[1
]}

Vuppugalla, Ragini ^{[1
]}

Zhao, Qihong ^{[1
]}

Carter, Percy H. ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ 08543 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2021年 / 12卷 / 06期

关键词：

CC chemokine receptor 2 (CCR2); CCR2; antagonist; Monocyte chemoattractant protein-1; Multiple sclerosis; TARGETS; BIOLOGY;

D O I：

10.1021/acsmedchemlett.1c00082

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

To improve the metabolic stability profile of BMS-741672 (1a), we undertook a structure-activity relationship study in our trisubstituted cyclohexylamine series. This ultimately led to the identification of 2d (BMS-753426) as a potent and orally bioavailable antagonist of CCR2. Compared to previous clinical candidate la, the tert-butyl amine 2d showed significant improvements in pharmacokinetic properties, with lower clearance and higher oral bioavailability. Furthermore, compound 2d exhibited improved affinity for CCRS and good activity in models of both monocyte migration and multiple sclerosis in the hCCR2 knock-in mouse. The synthesis of 2d was facilitated by the development of a simplified approach to key intermediate (4R)-9b that deployed a stereoselective reductive amination which may prove to be of general interest.

引用

页码：969 / 975

页数：7

共 50 条

[41] Discovery of potent, orally bioavailable CCR5 antagonists - 2.
Palani, A
Shapiro, S
Josien, H
Bara, T
Clader, J
Greenlee, W
Tagat, J
Steensma, R
McCombie, S
Neustadt, B
Pushpavanam, P
Chan, TM
Evans, A
Blythin, D
Ganguly, A
Piwinski, J
Dan, N
Baroudy, B
Endres, M
Strizki, J
Vantuno, N
Cox, K
Broske, L
Zhang, X
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U5 - U5
[42] Discovery of BMS-561389/DPC 906, a highly potent, selective and orally bioavailable Factor Xa inhibitor.
Lam, PYS
Quan, M
He, M
Li, RH
Clark, CG
Pinto, DJP
Teleha, CA
Alexander, RS
Rossi, KA
Wright, MR
Bai, SA
He, K
Luettgen, JM
Wong, PC
Knabb, RM
Wexler, RR
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U14 - U14
[43] Discovery of MK-0974: A potent, orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist for the treatment of migraine
Paone, Daniel V.
Shaw, Anthony
Nguyen, Diem
Burgey, Chris
Deng, James
Stump, Craig
Quigley, Amy
DeSolms, Jane
Kane, Stefanie
Koblan, Ken
Bednar, Rodney
Mallee, John
Mosser, Scott
Salvatore, Chris
McMasters, Daniel
Hershey, Jim
Corcoran, Halea
Lyle, Betsy
Wong, Brad
Roller, Shane
Miller-Stein, Cindy
Rowe, Janice
Yu, Sean
Graham, Sam
Vacca, Joseph
Williams, Theresa
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 549 - 549
[44] Hit-to-lead studies: The discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists
Baxter, A
Bennion, C
Bent, J
Boden, K
Brough, S
Cooper, A
Kinchin, E
Kindon, N
McInally, T
Mortimore, M
Roberts, B
Unitt, J
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) : 2625 - 2628
[45] Hit-to-lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists
Baxter, A
Cooper, A
Kinchin, E
Moakes, K
Unitt, J
Wallace, A
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (04) : 960 - 963
[46] CCX507, an Orally Bioavailable Antagonist of the Chemokine Receptor CCR9, for the Treatment of IBD
Walters, Matthew
Ebsworth, Karen
Sullivan, Tim
Zhang, Penglie
Powers, Jay
Bekker, Pirow
Dairaghi, Daniel
Seitz, Lisa
Ertl, Linda
Jaen, Juan
Schall, Thomas
GASTROENTEROLOGY, 2013, 144 (05) : S815 - S815
[47] Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Zhu, Chenyu
Ze, Shuyin
Zhou, Ronghui
Yang, Xinyu
Wang, Haojie
Chai, Xiaolei
Fang, Meimiao
Liu, Mingyao
Wang, Yonghui
Lu, Weiqiang
Xie, Qiong
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) : 4734 - 4754
[48] Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes
Xu, Guozhang
Gaul, Michael D.
Song, Fengbin
Du, Fuyong
Liang, Yin
DesJarlais, Renee L.
DiLoreto, Karen
Shook, Brian
Rentzeperis, Dennis
Santulli, Rosie
Eckardt, Annette
Demarest, Keith
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (20)
[49] Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
Zhang, Hefeng
Peng, Xia
Dai, Yang
Shao, Jingwei
Ji, Yinchun
Sun, Yiming
Liu, Bo
Cheng, Xu
Ai, Jing
Duan, Wenhu
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 3956 - 3975
[50] Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2
von Berg, Stefan
Xue, Yafeng
Collins, Mia
Llinas, Antonio
Olsson, Roine I.
Halvarsson, Torbjorn
Lindskog, Maria
Malmberg, Jesper
Jirholt, Johan
Krutrok, Nina
Ramnegard, Marie
Brannstrom, Marie
Lundqvist, Anders
Lepisto, Matti
Aagaard, Anna
McPheat, Jane
Hansson, Eva L.
Chen, Rongfeng
Xiong, Yao
Hansson, Thomas G.
Narjes, Frank
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (06): : 972 - 977

← 1 2 3 4 5 →